echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Forecast 2026 Global Pharmaceutical Sales Ranking TOP15 (above)

    Forecast 2026 Global Pharmaceutical Sales Ranking TOP15 (above)

    • Last Update: 2020-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    As the compilation/fresh pharmaceutical industry enters its new decade, the global pharmaceutical giants are busy launching new drugs and restructuring to focus on innovative products and new technologies.
    Despite the challenges from the new crown outbreak, industry analysts see the growth potential of many of the giants.
    , according to Agreed by EvaluatePharma, Roche will lead other big pharmaceutical companies in sales in 2026, driven by new products of oncology, multiple sclerosis and haemophilia.
    Pfizer, Johnson and Johnson, Novartis, AbbVie and Mercado will follow, with more than $50 billion in revenue from drug sales in 2026. High
    sales doesn't mean it's the fastest growing.
    analysts expect AstraZeneca and BMS to grow at the highest rates, with annual growth forecasts of 8.47 per cent and 8.23 per cent, respectively, in 2019-2026.
    is a detailed description of the global pharmaceutical giants' near- to medium-term outlook report: 1, Roche's 2019 sales: $48.2 billion expected to be 2026: $61.9 billion 2019-2026 CAGR: 3.62% of Roche topped the list is somewhat surprising because its three ace biologics (Anvetin, Herceptin, Merlot) will lose 9.6 billion Swiss francs from the competition for biologically similar drugs.
    but the new drugs are expected to catch up, and not just fill the gap.
    Roche also has an extensive oncology portfolio.
    this year, Tecentriq in conjunction with Anvitin was approved for first-line treatment of liver cancer, Tecentriq single drug was approved for first-line treatment of non-small cell lung cancer, Tecentriq combined chemotherapy new complementary treatment significantly improved the prognosis of patients with triple-negative breast cancer.
    , Tecentriq treats a variety of other types of tumors and is also clinically developed in Stage III.
    Credit Suisse, Tecentriq will sell $7 billion in cancer-assisted (postoperative) treatment alone.
    , new molecular entities such as AKT inhibitor ipatasertib are also on the horizon.
    but Roche is not just focused on cancer.
    one of the most successful product launches in the company's history is a neuroscience drug: Ocrevus, a multiple sclerosis drug that has been infusions only twice a year.
    as of the first quarter of 2020, Ocrevus has a 21% market share in the U.S. market and more than 40% of new and converted patients.
    short infusion time, 2 infusion frequency per year, will help Ocrevus gain a foothold in the market.
    in neuroscience, Roche also has risdiplam, which will be the first oral spinal muscular dystrophy (SMA) drug.
    Evaluate Pharma had previously forecast sales of $803 million in 2024.
    at the same time, IL-6 antibody satralizumab is awaiting the FDA's decision. Other growth drivers
    Roche included hemophilia drug Hemlibra, which reported sales of CHF 521 million in the first quarter, up 146 percent year-on-year.
    defending the haemophilia franchise, Roche acquired Gene Therapy company Spark Therapeutics.
    2, Pfizer 2019 Sales: $46.1 billion Expected 2026 Sales: $56.1 billion 2019-2026 CAGr: 2.83% According to Evaluate's forecast, Pfizer's annual growth rate will be 2.83% in 2019-2026, and sales will be more than $5 billion higher than in 2019.
    to achieve this, Pfizer will certainly need to rely on its lucrative biopharmaceutical brand, which achieved an impressive 12 per cent growth in the first quarter and revenues of more than $10bn.
    Pfizer's five core products, Vyndaqel, Eliquis, Ibrance, Prevnar and Xeljanz, will bring the company a bright future.
    the five products will not face patent losses until 2025, giving Pfizer plenty of room to identify strategic acquisitions or further investment pipelines to sustain growth in the coming years.
    pipeline, the new generation of 20-price pneumonia vaccine will be prevnar 13 upgrade products, in Phase III clinical success, is expected to submit a listing application by the end of the year.
    these strong products and pipelines will boost Pfizer's growth by 3 percent after the spin-off.
    but the split didn't go well, with EU regulators saying in April that Mylan and Upjohn overlapped in cardiovascular, musculoskeletal, neurological and urinary diseases.
    and the U.S. review continues and has been delayed because of the outbreak.
    3, Johnson and Johnson 2019 sales: $42.4 billion expected 2026 sales: $54.6 billion 2019-2026 COMPOUND annual growth rate: 3.75 percent of Johnson and Johnson is betting heavily on the pharmaceutical business, due to the introduction of new products and brand expansion, sales are expected to grow rapidly in the next few years, with sales expected to exceed $54 billion in 2026, making it among the top three global.
    Johnson and Johnson, the company's largest division, earned $42.2 billion last year.
    consumer health revenue of $13.9 billion and medical device revenue of $26 billion.
    pharmaceutical business was not only the biggest sales last year, but revenue growth was also strongest, at 5.8 percent. Oncology has been a strong driver in the
    pharmaceutical business, with franchise revenue up 11.9 percent to $10.7 billion in 2019.
    in addition to tumors, Johnson and Johnson Immunology generated nearly $14 billion in 2019, up 7.9 percent from the previous year.
    Johnson and Johnson Neuroscience franchise revenue rose 6.6 percent to $6.3 billion, while sales of cardiovascular, metabolic and other drugs fell 9.7 percent to $5.2 billion.
    some of Johnson's heavyweights are growing strongly, but executives believe there are more opportunities in the pipeline.
    in 2020, Zytiga's follow-up product, Erleada, the antidepressant Spravato, the blood cancer drug Imbruvica, the psoriasis drug Tremfya, the cancer drug Darzalex and the diabetes drug Invokana, will achieve potential brand expansion.
    , the company has just received approval for a new Ebola vaccine in the European Union and may have received EU approval for the HIV drug rilpivirine by the end of the year.
    industry analysts are also very bullish about the prospects for its hematological assets, CAR-T therapy JNJ-4528 and bispecific antibody teclistamab.
    4, Novartis 2019 sales: $46.08 billion projected 2026 sales: $54.25 billion 2019-2026 CAGr: 2.36% Novartis has a broad portfolio of star drugs covering immunology, cardiology, neuroscience, oncology and more.
    the company is aggressively expanding its business to include both new indications and new treatments.
    Over the past few years, Novartis has entered several new areas: through the acquisition of Advanced Accelerator S. and Endocyte to establish a radioactive drug business, through the acquisition of AveXis into the gene therapy space, through the acquisition of The Medicines Company into the RNA treatment field and the expansion of the heart portfolio.
    at the same time, the company sold its over-the-counter drug business to its joint venture partner, GlaxoSmithKline (GSK), to spin off its ophthalmology business, Alcon, but tried to abandon its U.S. franchise of Sandex's oral generics business but failed to get approval from the Federal Trade Commission within the scheduled time frame.
    currently, Novartis' leading portfolio is IL-17 Inhibitor Cosentyx, with sales of $3.55 billion in 2019, up 25% year-on-year.
    but the drug could face some new competition from Theaves IL-23 inhibitor Skyrizi, which beat Cosentyx in a psoriasis head-to-head study.
    another major growth driver in Novartis is the heart-decay drug Entresto, which reported sales of $1.73 billion in 2019, up 68 percent from a year earlier.
    in a Phase III trial last year, Entresto missed a statistical lying point in reducing death sepsis (HFpEF) heart failure (HFpEF) and emergency hospitalization rates, but after talking to the FDA, applied for new indications that could help Entresto achieve its $5 billion annual sales goal.
    then SMA gene therapy Zolgensma.
    now, the drug has reached a bottleneck in the U.S., treating about 100 patients every quarter with sales of $200 million.
    the drug was approved in Japan and Europe in the first half of this year, and Novartis is looking forward to these approvals to help achieve sales growth.
    is also developing an injection of Zolgensma into the vertebral tube, which could steal the market share of The Sieok Spinraza.
    Oncology is a key area of Novartis, and Kisqali has been accelerated to show that it can help HR/HER2-metastatic breast cancer survive longer, regardless of menopausal status.
    now, the drug will compete with Pfizer's market-leading Ibrance and Lilly Verzenio.
    Novartis is also testing Kisqali as an auxiliary treatment for HR/HER2-early-stage breast cancer, which is expected to be announced in 2022.
    , met inhibitor Tabrecta has just received FDA approval to treat MET mutation-controlled non-small cell lung cancer and will compete with Merck Tepmetko.
    pipeline, Novartis has cholesterol-lowering therapy inclisiran.
    Despite the flat performance of the PCSK9 antibody drug on the market, Novartis hopes to build a blockbuster product based on its business experience in the field of cardiology and inclisiran's innovative RNAi mechanism and low frequency of administration.
    , using the leukemia drug Arzerra to redevelop the drug of atumumab, which is used to repurpose multiple sclerosis, has the potential to become a challenger to Roche Ocrevus.
    Novartis is counting on the Chinese market to drive its growth.
    in the five years to 2024, Novartis plans to get approval of more than 50 new drugs in China, and hopes to double its current annual sales of $2.2 billion.
    for the future, Novartis aims to simultaneously submit applications in China and the U.S. and Europe.
    5, AbbVie 2019 sales: $32.35 billion projected 2026 sales: $53.56 billion 2019-2026 CAGr: 1.84 percent Of this list, AbbVie changed the most from last year, thanks to the acquisition of Aer Ingen.
    , but Evaluate expects that even after a large-scale acquisition, AbbVie is not without the possibility of considering further action.
    AbbVie's annual growth rate of 1.84 per cent in 2019-2026 may be necessary.
    , after all, the competition for Humira's biosimilars will be fierce, and after years of defending the franchise, Humira will face competition in the U.S. for many biosimilar stakes starting in early 2023.
    in Europe, Humira is already competing with biosimilars and sales are falling.
    AbbVie is selling Humira's follow-up products, Skyrizi and Rinvoq, to treat plaque psoriasis and rheumatoid arthritis, respectively, and more indications are expected in the future. Rick Gonzalez, chief executive of
    , told JPMorgan's healthconference conference earlier this year that the drugs could lead to sales peaking at nearly $20 billion over Humira in the future.
    While Humira's loss of exclusive rights in 2023 will hurt, analysts at RBC Capital Markets believe AbbVie will continue to grow because its pipeline is currently undervalued and visibility and confidence will improve over the next few years.
    , the company has just signed a bispecific antibody agreement with Genmab and intends to do more.
    6, Mercadon 2019 Sales: $40.9 billion Projected 2026 Sales: $51.96 billion 2019-2026 CAGr: 3.48% Mercadon heavy immuno-oncology product Keytruda is continuing to drive the company's revenue trajectory, but CEO Ken Frazier is working behind the scenes to ensure the company has other opportunities beyond this fast-growing cancer drug.
    is forecast to see sales of Mercayon grow to $52 billion in 2026, up from $46.8 billion last year, thanks in large part to Keytruda.
    , Evaluate predicts that Keytruda will have sales of $24.3 billion in 2026, overtaking Humira as the best-selling drug of 2026.
    these numbers are possible because Mercadon has been expanding Keytruda's market since the FDA first approved Keytruda for melanoma in 2014.
    currently treating indications has covered 17 types of cancer, including 2 open-ended cancer type indications, that is, not based on the location of the cancer in the body, but on what biomarkers the tumor has.
    , however, Ken Frazier and his team of executives are well aware that they are under pressure to diversify their product lines and pipelines.
    in the fourth quarter of last year's earnings report, Ken Frazier said the company would spin off its women's health and biosimilars division to focus more on building prescription drug pipelines.
    7, Sanofi 2019 sales:
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.